Foresite Capital, an equity firm that specializes in companies involved in provision of healthcare products and services, announced on April 24th 2017 that it has a new venture partner in its team. The new partner is none other than the seasoned scientific researcher, Dr. Molly He. She served as a senior director at Illumina, and has over a decade’s experience in the pharmaceutical industry. She also spent a few years at Pacific Biosciences where she headed the protein sciences department. Dr. Molly He is an authority in the drug development industry who has written numerous papers on the subject. Jim Tananbaum, the CEO of Foresite Capital, said that the company was thrilled to have Dr. He join the team. She expressed her excitement about joining Foresite Capital and looks forward to working with her new team.
About Jim Tananbaum
Jim Tananbaum is a seasoned investor in the pharmaceuticals and healthcare industry. He has over 2 decades’ experience in the industry and is an investment expert. He started Foresite Capital in 2010 to help remarkable healthcare companies (both public and private) grow and improve their products and services. Jim lives in San Francisco from where he runs the company and learn more about Jim.
Prior to forming Foresite Capital, he worked with Sierra Ventures and Prospect Venture Partners among other venture capital firms. During his time at these companies, he learnt all about running a venture capital firm, and this experience is what has enabled his company to be so successful in just 7 years. Jim has a keen interest in companies in the healthcare and pharmaceuticals industry. Some of the companies Foresite Capital has invested in include Amerigroup, Jazz Pharmaceuticals, Healtheon, and Amira Pharmaceuticals among others. Jim Tananbaum holds an MBA from Harvard Business School and a Doctor of Medicine from Harvard School of Medicine and Jim of Twitter.
It is clear that Foresite Capital is under very good leadership; it is no wonder that it continues to do so well. Dr. He’s experience and expertise in the pharmaceutical industry makes her well suited for the job as she can help a great deal with Foresite Capital’s investment decisions. The company is bound to do even better with such a powerful combination of venture partners.
More visit: https://www.forbes.com/profile/jim-tananbaum/